13F reference period
Q2 2026
Security Snapshot
First Trust Exchange-Traded Fund VI - First Trust Nasdaq Pharmaceuticals ETF (FTXH) Institutional Ownership
CUSIP: 33738R837
13F Institutional Holders and Ownership History from Q4 2016 to Q3 2026
Institutions Reporting
30
Shares (Excl. Options)
618.25K
Full value: 618,249 · shares · 30 Jun 2026Price
$38.19
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / First Trust Nasdaq Pharmaceuticals ETF
- Symbol
- FTXH
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 618,249
- Total 13F value
- $23,610,198
- Portfolio coverage rank
- 0%
- Share change
- +67,002
- Value change
- +$2,662,418
- Number of holders
- 30
- Shares outstanding
- 25,651,329
- SEC-reported price per share
- $40.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- FTXH - First Trust Exchange-Traded Fund VI - First Trust Nasdaq Pharmaceuticals ETF is tracked under CUSIP 33738R837.
- 30 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 32 to 30 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$18.89M
Full value: $18,889,661 · USD · 31 Mar 2026.$23.61M
Full value: $23,610,198 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 30 institutions filings for Q2 2026.
Security key
33738R837
13F reference period
Q2 2026
13F holders
30
13D/G owners
2
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 33738R837:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
FTXH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FIRST TRUST PORTFOLIOS LP | 75% | -2.7% | $792,714,394 | -$19,064,049 | 19,115,370 | -2.3% | First Trust Portfolios L.P. | 30 Sep 2026 |
| TRUIST FINANCIAL CORP | 0.2% | -88% | $2,524,910 | +$363,236 | 60,885 | +17% | TRUIST FINANCIAL CORP | 30 Sep 2026 |
As of 30 Jun 2026,
30
institutional investors reported holding
shares of
First Trust Exchange-Traded Fund VI - First Trust Nasdaq Pharmaceuticals ETF (FTXH).
This represents
2.4%
of the company’s total
outstanding shares.
618.25K
Full value: 618,249 · shares · 30 Jun 202625.65M
Full value: 25,651,329 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
40
Headline period
Q2 2026
Rows shown
1-25 of 40
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,088,570 | $45,134,017 | +$34,513,068 | $41.47 | 17 |
| 2026 Q2 | 618,249 | $23,610,198 | +$2,662,418 | $38.19 | 30 |
| 2026 Q1 | 550,491 | $18,889,661 | +$6,505,512 | $34.36 | 32 |
| 2025 Q4 | 361,422 | $11,907,418 | +$3,847,625 | $32.94 | 26 |
| 2025 Q3 | 246,799 | $7,037,519 | +$168,055 | $28.52 | 19 |
| 2025 Q2 | 241,138 | $6,179,131 | -$192,455 | $25.63 | 18 |
| 2025 Q1 | 246,905 | $6,786,524 | +$933,210 | $27.49 | 20 |
| 2024 Q4 | 213,864 | $5,776,086 | -$1,338,484 | $26.97 | 21 |
| 2024 Q3 | 260,227 | $7,503,090 | -$946,953 | $28.84 | 21 |
| 2024 Q2 | 297,995 | $8,120,682 | +$196,096 | $27.24 | 24 |
| 2024 Q1 | 290,802 | $8,134,702 | -$1,130,461 | $28.01 | 19 |
| 2023 Q4 | 333,321 | $8,871,675 | -$1,540,978 | $26.62 | 22 |
| 2023 Q3 | 397,511 | $10,162,214 | -$2,683,040 | $25.57 | 18 |
| 2023 Q2 | 493,239 | $12,916,871 | -$5,199,326 | $26.19 | 25 |
| 2023 Q1 | 692,309 | $18,079,789 | -$4,274,240 | $26.10 | 31 |
| 2022 Q4 | 801,329 | $21,979,181 | +$829,456 | $27.43 | 33 |
| 2022 Q3 | 760,789 | $18,286,404 | -$467,169 | $24.04 | 25 |
| 2022 Q2 | 734,967 | $19,420,643 | +$11,015,802 | $26.43 | 19 |
| 2022 Q1 | 317,070 | $8,433,661 | +$1,504,329 | $26.60 | 16 |
| 2021 Q4 | 260,685 | $7,056,706 | -$1,573,117 | $27.07 | 17 |
| 2021 Q3 | 320,179 | $8,225,579 | -$7,725,925 | $25.79 | 16 |
| 2021 Q2 | 600,687 | $16,015,588 | +$3,749,055 | $25.89 | 17 |
| 2021 Q1 | 465,034 | $11,994,163 | -$4,278,709 | $25.56 | 18 |
| 2020 Q4 | 556,299 | $14,336,577 | +$3,583,367 | $25.77 | 12 |
| 2020 Q3 | 436,251 | $10,564,408 | +$2,640,518 | $24.08 | 12 |